Article Sidebar
Views pdf: 52
THE SURVEY OF HER2 GENE STATUS IN THE BREAST CANCER GROUP WITH A HER2 (2+) AND RELATED FACTORS
Main Article Content
Abstract
Background: Breast cancer is currently a cancer with the highest incidence rate among others common cancers and is the leading cause of death for women around the world. In Vietnam, although there are many studies on receptors in breast cancer, there is no in-depth research on HER2 (2+) status. Determining the rate of HER2 gene amplification and related factors in the breast cancers group with a expressing HER2 (2+) based on FISH technique will reduce false positive cases, improve prognosis and treatment. Methods: Cross-sectional retrospective review of 302 paraffin embedded tissue blocks. Tissue samples with HER2(2+) Immunohistochemistry results will be subjected to fluorescence in situ hybridization (FISH) on the HER2/CEP17 signal pair performed at the Ho Chi Minh Oncology Hospital in 2022. Results: The main age group is from 41 to 50, with the average age of 51.85 ± 10.60. The rate of HER2 gene amplification is 47.68%. The average HER2/CEP17 signal recorded was 2.2285 ± 1.47990, the highest signal ratio recorded was 10.00. In our research, there were 79 cases of chromosome 17 polyploidy. The detection rate of chromosome 17 polyploidy was mainly in those cases with HER2/CEP17 ratio < 2. Conclusion: There are 47.68% of HER2(2+) cases have gene amplification. There is a correlation between HER2 and other breast cancer receptors.
Article Details
References
2. Vang R, Cooley LD, Harrison WR, Reese T, Abrams J. Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma. Am J Clin Pathol. 2000;113(5):669-674. doi:10.1309/LTUM-QG95-YRY3-L96U
3. Escrivá-de-Romaní S, Arumí M, Bellet M, Saura C. HER2-positive breast cancer: Current and new therapeutic strategies. The Breast. 2018;39: 80-88. doi: 10.1016/J.BREAST. 2018.03.006
4. Yang L, Chen M, Pu T, et al. The differences of clinicopathologic characteristics among subgroups of reclassified HER2 fluorescence in situhybridization (FISH) according to the ASCO/CAP 2018 breast cancer HER2 testing guidelines. J Clin Pathol. 2020;73(5). doi:10.1136/ jclinpath-2019-206222
5. Trieu PD, Mello-Thoms C, Brennan PC. Female breast cancer in Vietnam: a comparison across Asian specific regions. Cancer Biol Med. 2015;12(3). doi:10.7497/ j.issn.2095-3941. 2015.0034
6. Phan Thị Đỗ Quyên, Nguyễn Việt Cường. Đánh giá hiệu quả điều trị của liệu pháp nội tiết bổ trợ trong ung thư vú. Journal of Clinical Medicine- Hue Central Hospital. 2022;(82). doi:10.38103/jcmhch.82.14
7. Yap YS, Singh AP, Lim JHC, et al. Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers. NPJ Breast Cancer. 2018;4(1). doi:10.1038/s41523-018-0070-x
8. Aznab M, Izadi B, Amirian F, Khazaei S, Madani SH, Ramezani M. Comparison of Immunohistochemical Methods (IHC) and Fluorescent in Situ Hybridization (FISH) in the Detection of HER 2/Neu Gene in Kurdish Patients with Breast Cancer in Western Iran. Int J Hematol Oncol Stem Cell Res 2022;16(4). doi:10.18502/ ijhoscr.v16i4.10879
9. Kim JW, Kim JH, Im SA, et al. HER2/NST17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ
hybridization-positive metastatic breast cancer. Cancer Chemother Pharmacol. 2013;72(1). doi:10.1007/s00280-013-2174-1
10. Halilovic A, Verweij DI, Simons A, et al. HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study. Sci Rep. 2019;9(1):11679. Published 2019 Aug 12. doi:10.1038/s41598-019-48212-2